Understand the source comparison
Peptide Compounding Pharmacy Changes 2026: Regulatory Comparison
API Sourcing FDA facility registration (21 CFR 207.20) sufficient Full cGMP certification required for all therapeutic-use suppliers Effective Jan 15, 2026; 90-day grace period ended Apr 15, 2026 60% reduction in legally compliant peptide API suppliers; custom
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- API Sourcing
- FDA facility registration (21 CFR 207.20) sufficient
- Full cGMP certification required for all therapeutic-use suppliers
- Effective Jan 15, 2026; 90-day grace period ended Apr 15, 2026
- 60% reduction in legally compliant peptide API suppliers; custom and niche peptides hardest hit
- GLP-1 Shortage Compounding
- Legal during FDA shortage designation (semaglutide: Mar 2022–Feb 2026; tirzepatide: Dec 2022–Mar 2026)
- No longer permitted. Brand supply restored; compounding requires new shortage declaration
- Semaglutide wind-down ended Apr 20, 2026; tirzepatide May 9, 2026
- $2.4B compounding revenue eliminated; many 503B facilities downsized or closed
- 503A Interstate Shipping
- Vague "medically necessary quantity" standard; bulk orders common under blanket prescriptions
- 90-day supply maximum; prescriber attestation of no commercial alternative required
- Effective Mar 1, 2026; enforcement began May 1, 2026
- Research labs lost primary peptide procurement pathway; 503A pharmacies exited bulk peptide business